New York State Medicaid Drug Utilization Review Board
Meeting Agenda

The Drug Utilization Review (DUR) Board will meet on April 27, 2017, from 9:00 a.m. to 4:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda Items

A. Preferred Drug Program (PDP)

The DUR Board will review therapeutic classes listed below, as they pertain to the PDP.

- The DUR Board will review clinical and financial information, to recommend preferred and non-preferred drugs.
- For therapeutic classes currently subject to the PDP*, the DUR Board will only consider clinical information which is new since the previous review of the therapeutic class and then consider financial information.

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials (comparative evidence is preferred, or placebo controlled when no head-to-head trials are available). Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of re-review and submission is discouraged.

- Those wishing to submit new clinical information must do so in an electronic format by April 12, 2017 or the DUR Board may not have ample time to review the information.

* The current preferred and non-preferred status of drugs subject to the Preferred Drug List (PDL) may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

1. Opioids - Long Acting

(Previous review date: April 27, 2016)
Belbuca (buprenorphine) buccal film, Butrans (buprenorphine) Patch, Conzip (tramadol ER), Duragesic (fentanyl patch), Embeda ER (morphine/naltrexone), Exalgo (hydromorphone HCl ER), fentanyl patch, hydromorphone ER, Hysingla ER (hydrocodone bitartrate), Kadian (morphine sulfate SR), morphine sulfate SR/ER, MS Contin (morphine sulfate CR), Nucynta ER (tapentadol ER), Opana ER (oxymorphone ER), oxycodone ER, Oxycontin (oxycodone HCl CR), oxymorphone ER, tramadol ER, Xtampza ER (oxycodone), Zohydro ER (hydrocodone ER)

2. Angiotensin Converting Enzyme Inhibitors (ACEIs)

(Previous review date: April 22, 2015)
Accupril (quinapril), Altace (ramipril), benazepril, captopril, enalapril, Epaned (enalapril), fosinopril, lisinopril, Lotensin (benazepril), Mavik (trandolapril), moexipril, perindopril, Prinivil
3. HMG-CoA Reductase Inhibitors (Statins)  
(Previous review date: April 19, 2012)
Altopenv (lovastatin extended-release), atorvastatin, atorvastatin/amlodipine, Caduet (atorvastatin/amlodipine), Crestor (rosuvastatin), fluvastatin, fluvastatin ER, Lescol XL (fluvastatin XL), Lipitor (atorvastatin), Livalo (pitavastatin), lovastatin, Pravachol (pravastatin), pravastatin, rosuvastatin, simvastatin, Vytorin (simvastatin/ezetimibe), Zocor (simvastatin)

4. Anticonvulsants - Second Generation  
(Previous review date: September 15, 2016)
Banzel (rufinamide), Briviact (brivaracetam), felbamate, Felbatol (felbamate), Fycompa (perampanel), gabapentin, Gabitril (tiagabine), Keppra/Keppra XR (levetiracetam), Lamictal/Lamictal XR (lamotrigine), lamotrigine, lamotrigine ER, levetiracetam, levetiracetam ER, Lyrica (pregabalin), Neurontin (gabapentin), Onfi (clobazam), Potiga (ezogabine), Qudexy XR (topiramate), Sabril (vigabatrin), Spritam (levetiracetam), tiagabine, Topamax (topiramate), topiramate, topiramate ER, Trokendi XR (topiramate ER), Vimpat (lacosamide), Zonegran (zonisamide), zonisamide

5. Antipsychotics - Second Generation  
(Previous review date: April 27, 2016)
Abilify (aripiprazole) (solution, tablet), aripiprazole/aripiprazole ODT, clozapine/clozapine ODT, Clozaril (clozapine), Fanapt (iloperidone), FazaClo (clozapine), Geodon (ziprasidone), Invega (paliperidone ER), Latuda (lurasidone), Nuplazid (pimavanserin), olanzapine/olanzapine ODT, paliperidone ER, quetiapine, quetiapine ER, Rexulti (brexipiprazole), Risperdal (risperidone), risperidone, Saphris (asenapine), Seroquiel (quetiapine), Seroquel XR (quetiapine), Versacloz (clozapine), Vraylar (cariprazine), ziprasidone, Zyprev (olanzapine)

6. Central Nervous System (CNS) Stimulants  
(Previous review date: April 27, 2016)
Adderall (amphetamine salt combo), Adderall XR (amphetamine salt combo XR), Adzenys XR-ODT (amphetamine), amphetamine salt combo ER, amphetamine salt combo IR, Aptensio XR (methylphenidate ER), armodafinil, Concerta (methylphenidate ER), Daytrana (methylphenidate ER patch), Desoxyn (methamphetamine), Dexedrine (dextroamphetamine ER), dexamphetamine, dexamphetamine ER, dextroamphetamine (solution, tablet), dextroamphetamine ER, DyanaVel XR (amphetamine ER oral suspension), Evekeo (amphetamine sulfate), Focalin (dexamphetamine), Focalin XR (dexamphetamine XR), Metadate CD (methylphenidate CD), Metadate ER (methylphenidate ER), methamphetamine, Methylin (methylphenidate), methylphenidate (chewable tablet, solution, tablet), methylphenidate CD/ER/SR, modafinil, Nuvigil (armodafinil), Procentra (dextroamphetamine sulfate solution), Provigil (modafinil), Quillichew ER (methylphenidate ER), Quillivant XR (methylphenidate XR), Ritalin (methylphenidate), Ritalin LA (methylphenidate LA), Vyvanse (lisdexamfetamine dimesylate), Zenzedi (dextroamphetamine)

7. Multiple Sclerosis Agents  
(Previous review date: September 15, 2016)
Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone 20 mg/mL, Copaxone 40 mg/mL (glatiramer acetate), Extavia (interferon beta-1b), Gilenya
(fingolimod), Glatopa (glatiramer acetate), Plegridy (peginterferon beta-1A), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate), Zinbryta (daclizumab)

8. Antifungals - Topical
(Previous review date: April 24, 2014)
Alevazol OTC (clotrimazole), Ciclodan (ciclopirox), ciclopirox (cream, gel, suspension), clotrimazole OTC, clotrimazole/betamethasone, clotrimazole Rx, econazole, Ertaczo (sertaconazole), Exelderm (sulconazole), Extina (ketoconazole), Lamisil AT (terbinafine HCL), Lotrisone (clotrimazole/betamethasone), Luzu (luliconazole), Mentax (butenafine HCL), miconazole OTC, naftifine, Naftin (naftifine HCL), Nyamyc (nystatin), oxiconazole, oxiconazole nitrate, terbinafine OTC, tolnaftate OTC, Vusion (miconazole nitrate/zinc)

9. Anti-Infectives - Topical
(Previous review date: April 24, 2014)
Acanya (clindamycin/benzoyl peroxide), BenzaClin (clindamycin/benzoyl peroxide) (gel, pump), Benzamycin (erythromycin/benzoyl peroxide), Cleocin T (clindamycin), Clindacin (clindamycin), Clindagel (clindamycin), clindamycin (foam, gel, lotion solution, pledget), clindamycin/benzoyl peroxide, Duac (clindamycin/benzoyl peroxide), Erygel (erythromycin base/ethanol), erythromycin (gel, solution, pledget), erythromycin/benzoyl peroxide, Evoclin (clindamycin), Neuac (clindamycin/benzoyl peroxide), Onexton (clindamycin/benzoyl peroxide)

10. Glucagon-like Peptide-1 (GLP-1) Agonists
(Previous review date: April 22, 2015)
Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide ER), Soliqua (lixisenatide/insulin glargine), Tanzeum (albiglutide), Trulicity (dulaglutide), Victoza (liraglutide), Xultophy (liraglutide/insulin degludec)

11. Insulin, Long-Acting
(Previous review date: April 27, 2016)
Basaglar (insulin glargine), Lantus (insulin glargine), Levemir (insulin detemir), Toujeo (insulin glargine), Tresiba (insulin degludec)

12. Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
(Previous review date: September 18, 2014)
Farxiga (dapagliflozin), Invokamet/Invokamet XR (canagliflozin/metformin), Invokana (canagliflozin), Jardiance (empagliflozin), Synjardy (empagliflozin/metformin), Xigduo XR (dapagliflozin/metformin)

13. Anticoagulants - Oral
(Previous review date: April 22, 2015)
Coumadin (warfarin), Eliquis (apixaban), Jantoven (warfarin), Pradaxa (dabigatran), Savaysa (edoxaban), warfarin, Xarelto (rivaroxaban)

14. Platelet Inhibitors
(Previous review date: September 17, 2015)
Aggrenox (dipyridamole ER/aspirin), Brilinta (ticagrelor), clopidogrel, dipyridamole, dipyridamole/aspirin, Durlaza (aspirin extended-release), Effient (prasugrel), Plavix (clopidogrel), ticlopidine, Yosprala (aspirin/omeprazole), Zontivity (vorapaxar)
15. Epinephrine, Self-injected  
   (Initial Review)  
   Adrenaclick, epinephrine, EpiPen, EpiPen Jr.

16. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) - Ophthalmic  
   (Previous review date: June 27, 2013)  
   Acular (ketorolac), Acular LS (ketorolac), Acuvail (ketorolac tromethamine), bromfenac,  
   BromSite (bromfenac), diclofenac, flurbiprofen, Ilevro (nepafenac), ketorolac, Nevanac  
   (nepafenac), Ocufen (flurbiprofen), Prolensa (bromfenac)

17. Fluoroquinolones - Otic  
   (Previous review date: June 10, 2009)  
   Cipro HC (ciprofloxacin/hydrocortisone otic), Ciprodex (ciprofloxacin/dexamethasone otic),  
   ciprofloxacin, Floxin (ofloxacin), ofloxacin, Otovel (ciprofloxacin/fluocinolone)

18. Phosphate Binders/Regulators  
   (Previous review date: April 22, 2015)  
   Auryxia (ferric citrate), calcium acetate, Eliphos (calcium acetate), Fosrenol (lanthanum  
   carbonate), Phoslyra (calcium acetate), Renagel (sevelamer HCl), Renvela (sevelamer  
   carbonate), Velphoro (sucroferric oxyhydroxide)

19. Anticholinergics - COPD Agents  
   (Previous review date: April 27, 2016)  
   Anoro Ellipta (umeclidinium/vilanterol), Atrovent HFA (ipratropium), Bevespi Aerosphere  
   (glycopyrrolate/formoterol), Combivent Respimat (ipratropium/albuterol), Daliresp  
   (roflumilast), Incruse Ellipta (umeclidinium), ipratropium, ipratropium/albuterol, Seebri  
   Neohaler (glycopyrrolate), Spiriva (tiotropium), Spiriva Respimat (tiotropium), Stioltto  
   Respimat (tiotropium/olodaterol), Tudorza Pressair (aclidium bromide), Utibron Neohaler  
   (indacaterol/glycopyrrolate)

20. Corticosteroid/LA Beta-2 Adrenergic Agent Combinations - Inhaled  
   (Previous review date: April 24, 2014)  
   Advair Diskus (fluticasone/salmeterol), Advair HFA (fluticasone/salmeterol),  
   Breo Ellipta (fluticasone/vilanterol), Dulera (mometasone/formoterol), Symbicort  
   (budesonide/formoterol)

21. Corticosteroids - Intranasal  
   (Previous review date: April 24, 2014)  
   Beconase AQ (beclomethasone), budesonide, Dymista (azelastine/fluticasone), fluticasone,  
   flunisolide, mometasone, Nasonex (mometasone), Omnaris (ciclesonide), QNASL  
   (beclomethasone), Veramyst (fluticasone), Zetonna (ciclesonide)

**Agenda Timeline** (subject to change based on meeting proceedings)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:15</td>
<td>Welcome and Opening Comments</td>
</tr>
<tr>
<td>9:15 - 10:45</td>
<td>Public Comment Period</td>
</tr>
<tr>
<td>10:45 - 11:00</td>
<td>Break</td>
</tr>
</tbody>
</table>
11:00 - 1:00  Clinical reviews  
1:00 - 3:00  Lunch/Executive Session (financial reviews)  
3:00 - 3:45  Recommendations  
3:45 - 4:00  Final Comments and Adjournment  

Interested parties must notify the Department of Health (DoH) by April 19, 2017 of their request to address the DUR Board during the public comment period. Requests may be made by calling 518-486-3209 or e-mailing dur@health.ny.gov. (Please reference DUR Board Speaker Request).

Public comments are limited to therapeutic classes on the agenda and new clinical information for the PDP classes under review. Comments must be brief (2 minutes) and the total comment period will not exceed ninety (90) minutes. DoH reserves the right to limit the number of interested parties providing public comment in order to meet meeting timelines and accomplish meeting objectives.

All written statements must be received in an electronic format by April 19, 2017. Written statements should summarize key points and may not exceed two (2) pages in length. Any studies cited should be referenced, with the primary source of funding included.

Clinical information must be submitted in an electronic format by April 12, 2017, or the Board may not have ample time to review the information. For the therapeutic classes currently subject to the PDP, submitted clinical information must be new since the previous review of the therapeutic class.

Any information regarding the DUR Board must be sent to the DoH to ensure distribution to all members. Interested parties should not contact or send any information directly to DUR Board members.